146 related articles for article (PubMed ID: 11423528)
1. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? A response to Grover et al.
Egede LE
Diabetes Care; 2001 Jul; 24(7):1306-7. PubMed ID: 11423528
[No Abstract] [Full Text] [Related]
2. Commentary: A new approach to atherogenic dyslipidemia.
Reasner CA
Postgrad Med; 2005 Apr; 117(4):13-6. PubMed ID: 15842128
[No Abstract] [Full Text] [Related]
3. Normocholesterolaemic dyslipidaemia: is there a role for fibrates?
Tallis GA
Med J Aust; 2001 Jun; 174(11):610; author reply 611. PubMed ID: 11453340
[No Abstract] [Full Text] [Related]
4. [Metabolic effects of hypolipemic drugs on aged type 2 diabetes].
Palel G; Coman A; Petrovanu R; Ungureanu D
Rev Med Chir Soc Med Nat Iasi; 2001; 105(3):518-20. PubMed ID: 12092185
[TBL] [Abstract][Full Text] [Related]
5. [Overviews of fibrate].
Tada N
Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
[No Abstract] [Full Text] [Related]
6. New strategies for the treatment of diabetic dyslipidemia.
Haffner SM; Goldberg RB
Diabetes Care; 2002 Jul; 25(7):1237-9. PubMed ID: 12087025
[No Abstract] [Full Text] [Related]
7. [Dyslipidemia in diabetes mellitus: statins treatment raises survival of patients].
Shestakova MV
Ter Arkh; 1999; 71(1):67-9. PubMed ID: 10097307
[No Abstract] [Full Text] [Related]
8. Getting more people on statins.
Roberts WC
Am J Cardiol; 2002 Sep; 90(6):683-5. PubMed ID: 12231110
[No Abstract] [Full Text] [Related]
9. [Treatment of blood lipids abnormality in patients with diabetes mellitus].
Wang XM
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Apr; 29(4):379-84. PubMed ID: 19526769
[No Abstract] [Full Text] [Related]
10. Managing dyslipidemia in adults with diabetes.
Haffner SM
Manag Care; 2003 Sep; 12(9 Suppl):10-5. PubMed ID: 14535130
[No Abstract] [Full Text] [Related]
11. Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence.
Wong MC; Wang HH; Liu KS
Int J Clin Pract; 2011 Dec; 65(12):1321-2. PubMed ID: 22093540
[No Abstract] [Full Text] [Related]
12. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Adkins JC; Faulds D
Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Farnier M; Retterstøl K; Steinmetz A; Császár A
Diab Vasc Dis Res; 2012 Jul; 9(3):205-15. PubMed ID: 22228773
[TBL] [Abstract][Full Text] [Related]
14. LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation.
Sathyapalan T; Atkin SL; Kilpatrick ES
Ann Clin Biochem; 2015 Jan; 52(Pt 1):180-2. PubMed ID: 24719214
[TBL] [Abstract][Full Text] [Related]
15. Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes.
Ashraf R; Amir K; Shaikh AR
J Pak Med Assoc; 2005 Aug; 55(8):324-7. PubMed ID: 16164158
[TBL] [Abstract][Full Text] [Related]
16. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
Farnier M; Steinmetz A; Retterstøl K; Császár A
Clin Ther; 2011 Jan; 33(1):1-12. PubMed ID: 21397769
[TBL] [Abstract][Full Text] [Related]
17. Hyperlipidaemia and cardiovascular disease.
Sussekov AV
Curr Opin Lipidol; 1998 Apr; 9(2):175-7. PubMed ID: 9559278
[No Abstract] [Full Text] [Related]
18. Response of high-density lipoproteins to hypolipidemic drugs according to their initial level.
Kolovou GD; Fostinis YP; Bilianou HI; Cokkinos DV
Am J Cardiol; 1995 Feb; 75(4):293-5. PubMed ID: 7832145
[No Abstract] [Full Text] [Related]
19. [Efficacy and safety of simvastatin in patients with hypercholesterolemia (results of a Multicenter Clinical Study)].
Kukharchuk VV; Bubnova MG; Katel'nitskaia LI; Nikitin IuP; Ol'binskaia LI;
Kardiologiia; 2003; 43(5):42-7. PubMed ID: 12891239
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia.
Molcányiová A; Stancáková A; Javorský M; Tkác I
Pharmacol Res; 2006 Sep; 54(3):203-7. PubMed ID: 16737822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
